US 12,479,852 B2
Compounds, compositions, and methods for protein degradation
Jun Qi, Sharon, MA (US); Scott Armstrong, Wayland, MA (US); and Lei Wu, Shanghai (CN)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Appl. No. 17/622,091
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
PCT Filed Jun. 25, 2020, PCT No. PCT/US2020/039638
§ 371(c)(1), (2) Date Dec. 22, 2021,
PCT Pub. No. WO2020/264172, PCT Pub. Date Dec. 30, 2020.
Claims priority of provisional application 62/867,642, filed on Jun. 27, 2019.
Prior Publication US 2022/0389023 A1, Dec. 8, 2022
Int. Cl. C07D 487/08 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/08 (2013.01) [A61P 35/00 (2018.01)] 21 Claims
 
1. A compound of Formula I or Formula II:

OG Complex Work Unit Chemistry
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein
X is a bond, phenyl, or pyridyl;
L is an alkylene chain comprising 1 to 25 carbon atoms,
optionally wherein:
at least one, but no more than ten, —CH2— moieties of L are independently replaced with a moiety selected from —C(—O)—, —C(—O)—NR3— —NR3—C(═O)—, —C(═O)—O—, —O—C(═O)—, —NR3—C(═O)—NR3—, —O—C(═O)—NR3—, —NR3—C(═O)—O—, —O—, —S—, and —NR2—, provided the number of —CH2— moieties of L is larger than the collective number of —C(═O)—, —C(—O)—NR3— —NR3—C(═O)—, —C(═O)—O—, —O—C(═O)—, —NR3—C(═O)—NR3—, —O—C(═O)—NR3—, —NR3—C(═O)—O—, —O—, —S—, and —NR3— moieties of L, and provided there is at least one —CH2— between each —C(═O)—, —C(═O)—NR3— —NR3—C(═O)—, —C(═O)—O—, —O—C(═O)—, —NR3—C(═O)—NR3—, —O—C(═O)—NR3—, —NR3C(═O)—O—, —O—, —S—, and —NR2— moiety of L;
Z-L is —CH2-L, —O—CH2-L, or —NR3—CH2-L; and
R1, R2, and R3 are each independently selected from H and alkyl.